Combined pulmonary fibrosis and emphysema: A distinct underrecognised entity

European Respiratory Journal

Volumn 26, Issue 4, 2005, Pages 586-593

  Cottin, V ^a   Nunes, H ^b   Brillet, P Y ^b   Delaval, P ^c   Devouassaoux, G ^d,h   Tillie Leblond, I ^e   Israel Biet, D ^f   Court Fortune, I ^g   Valeyre, D ^b   Cordier, J F ^a   Carre P ^h   Chabot, F ^h   Chatte G ^h   Coetmeur D ^h   Crestani, B ^h   Dalphin, J C ^h   Dietemann, A ^h   Gentil, B ^h   Humbert, M ^h   Lacronique, J ^h   Mairesse, M ^h   Marchand, E ^h   Reynaud Gaubert, M ^h   more..

^a LOUIS PRADEL HOSPITAL   (France)

^b AVICENNE HOSPITAL   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g HÔPITAL NORD   (France)

^h NONE

Author keywords

Emphysema; Interstitial lung disease; Pulmonary arterial hypertension; Pulmonary fibrosis

Indexed keywords

CARBON MONOXIDE; CORTICOSTEROID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; PREDNISONE;

ABNORMAL RESPIRATORY SOUND; ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLUBBING FINGERS; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; EMPHYSEMA; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DIFFUSION; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OXYGEN THERAPY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SURVIVAL; TOTAL LUNG CAPACITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PULMONARY EMPHYSEMA; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SMOKING; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 26844449508     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00021005     Document Type: Article

References (27)

1. Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med 1990; 84: 365-369.
2. Hiwatari N, Shimura S, Takishima T. Pulmonary emphysema followed by pulmonary fibrosis of undetermined cause. Respiration 1993; 60: 354-358.
3. Doherty MJ, Pearson MG, O'Grady EA, Pellegrini V, Calverley PM. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 1997; 52: 998-1002.
4. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
5. Austin JH, Muller NL, Friedman PJ, et al. Glossary of terms for CT of the lungs: recommendations of the Nomenclature Committee of the Fleischner Society. Radiology 1996; 200: 327-331.
6. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, 5-40.
7. King TE Jr, Costabel U, Cordier JF, et al. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000; 161: 646-664.
8. Hansell D, Nicholson AG. Smoking-related diffuse parenchymal lung disease: HRCT-pathologic correlation. Semin Respir Crit Care Med 2003; 24: 377-391.
9. Wells AU, King AD, Rubens, MB, Cramer D, du Bois RM, Hansell DM. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 1997; 155: 1367-1375.
10. Copley SJ, Wells AU, Muller NL, et al. Thin-section CT in obstructive pulmonary disease: discriminatory value. Radiology 2002; 223: 812-819.
11. Vehmas T, Kivisaari L, Huuskonen MS, Jaakkola MS. Effects of tobacco smoking on findings in chest computed tomography among asbestos-exposed workers. Eur Respir J 2003; 21: 866-871.
12. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001; 164: 1171-1181.
13. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158: 49-59.
14. American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med 2003; 168: 818-900.
15. Seersholm N, Dirksen A, Kok-Jensen A. Airways obstruction and two year survival in patients with severe alpha 1-antitrypsin deficiency. Eur Respir J 1994; 7: 1985-1987.
16. Jebrak G, Brugieres O, Dauriat G, Mal H, Leseche G, Fournier M. Time-course changes in pulmonary haemodynamics in patients with idiopathic pulmonary fibrosis (IPF) waiting for lung transplantation (LT). Eur Respir J 2004; 24: Suppl. 48, 668S.
17. Weitzenblum E, Ehrhart M, Rasaholinjanahary J, Hirth C. Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. Respiration 1983; 44: 118-127.
18. Jezek V. The prognosis and development of pulmonary hypertension in idiopathic diffuse interstitial lung fibrosis. G Ital Cardiol 1984; 14: Suppl. 1, 39-45.
19. Kessler R, Faller M, Weitzenblum E, et al. "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164: 219-224.
20. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981; 36: 752-758.
21. Laaban JP, Diebold B, Zelinski R, Lafay M, Raffoul H, Rochemaure J. Noninvasive estimation of systolic pulmonary artery pressure using Doppler echocardiography in patients with chronic obstructive pulmonary disease. Chest 1989; 96: 1258-1262.
22. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997; 155: 242-248.
23. Schwartz DA, Merchant RK, Helmers RA, Gilbert SR, Dayton CS, Hunninghake GW. The influence of cigarette smoking on lung function in patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991; 144: 504-506.
24. Cherniack RM, Colby TV, Flint A, et al. Correlation of structure and function in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995; 151: 1180-1188.
25. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.
26. Wang Z, Zheng T, Zhu Z, et al. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Clin Invest 2000; 192: 1587-1599.
27. Lundblad LK, Thompson-Figueroa J, Leclair T, et al. Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype. Am J Respir Crit Care Med 2005; 171: 1363-1370.